Venous thromboembolism (VTE) is a global health concern with substantial morbidity and mortality[@ref1]. It is often asymptomatic and underdiagnosed, leading to long-term complications and reduced survival. Approximately 30 per cent of patients with symptomatic VTE manifest pulmonary embolism (PE), whereas others manifest deep vein thrombosis (DVT). Thus, it is a major health issue in western countries[@ref1]. VTE events remain a relatively common cause of death in hospitalized patients and almost 75 per cent of all VTE-related deaths are from hospital-acquired VTE[@ref1]. Earlier evidence suggests that hospital-acquired VTEs can be prevented given the availability of effective prophylaxis[@ref2][@ref3].

Earlier studies have demonstrated the increasing incidence of VTE in Asian populations[@ref4]. The incidence of post-operative DVT in Indian patients undergoing major lower limb surgery is as high (43.2 and 60% patients in the groups with and without prophylaxis, respectively) as seen in the Western world[@ref5]. It has been also shown that PE occurs frequently in Indian patients with symptomatic DVT; 40 per cent patients with DVT had high probability lung scan showing high prevalence of PE[@ref6]. In the Indian subset data of the global Prospective Registry On Venous thromboembolic Events (PROVE) registry, proximal plus calf DVTs were found in 54 per cent of Indian patients, proximal DVT in 17 per cent, and calf DVT in 13 per cent, compared with 52, 18, and 24 per cent in the global PROVE population, respectively[@ref7]. VTE is no longer a rarity in India with general surgical operations being the most common causes of post-operative DVT. Also, morbidity and mortality from VTE is a significant problem in India[@ref8].

The Eighth American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines (ACCP guidelines) help in the assessment of risk factors for VTE and recommend the appropriate use of prophylaxis to prevent VTE in patients at risk[@ref9]. Although the incidence of DVT in India is comparable to that in the Western countries, the awareness level of VTE is particularly low among Indians[@ref8]. The newly developed consensus/clinical practice guidelines provide recommendations for the continued management of patients with VTE, addressing specifically the risk stratification of VTE, and the appropriate use of low molecular weight heparins (LMWHs) in the prophylactic management of this condition[@ref10]. Earlier studies have demonstrated that thromboprophylaxis reduces adverse outcomes along with reduction in overall costs[@ref11][@ref12].

Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting (ENDORSE) study is a multinational, cross-sectional survey in both medical as well as surgical patients in a large number of hospitals worldwide. The study aimed to assess the number of patients at risk for VTE and the proportion that received effective prophylaxis as recommended by the ACCP guidelines[@ref13]. This study presents the risk factor profile and prophylaxis patterns in hospitalized Indian patients who participated in the ENDORSE study.

Material & Methods {#sec1-1}
==================

The detailed methodology of the ENDORSE study has been previously published[@ref13]. Briefly, the primary objective was to identify hospitalized patients at risk of VTE and to determine the proportion of patients receiving effective VTE prophylaxis. Patients ≥40 yr age in eligible medical wards (general medical, respiratory or cardiac wards) or ≥18 yr age in eligible surgical wards (general surgical and orthopaedic wards) were screened. The study excluded patients if their charts were unavailable, admitted to ineligible wards, were admitted solely for the treatment of VTE, were too young (age \<18 yr for surgical, \<40 yr for medical), admitted for diagnostic testing/minor operation (type of ward not specified), transfer patients, or their key information (birth year, surgery types, *etc*.) was missing. According to the national rules, the approval of the ethics committee at Nizam\'s Institute of Medical Sciences, Hyderabad, was obtained for the study in India.

The Indian component of the ENDORSE study was conducted according to the global protocol. In India, 2058 patients were enrolled from 10 hospitals between August 2006 and January 2007. These 10 hospitals were Nizam\'s Institute of Medical Sciences, Hyderabad; Southern Railway Hospital, Chennai; Chennai Port Trust Hospital, Chennai; Holy Family Hospital, New Delhi; Woodlands Medical Centre Ltd., Kolkata; Prince Aly Khan Hospital, Mumbai; MS Ramaiah Hospital, Bangalore; St John\'s Medical College Hospital, Bangalore; Rabindranath Tagore International Institute of Cardiac Science, Kolkata; and Gandhi Hospital, Hyderabad. Data were collected by reviewing the hospital charts and filling the relevant information in standardized case report forms. Patient demographics, admission and post-admission diagnoses, risk factors for VTE (as defined in ACCP guidelines)[@ref9], risk factors for bleeding, duration of hospitalization, and type of VTE prophylaxis (as defined in ACCP guidelines)[@ref9] were obtained.

*Statistical analysis*: A minimum of 450 patients were required per analysis group in order to assess the true occurrence of VTE risk at 25 per cent with a margin of error of 4 per cent. Quantitative data were expressed as median (inter-quartile range) and the number of non-missing data, while categorical data were expressed as number and percentage of the population. SAS version 9.1 (SAS Institute Inc., Cary, North Carolina, USA) was used for all statistical analyses.

Results {#sec1-2}
=======

The number of beds assessed and reasons for exclusion from assessment are shown in the [Fig](#F1){ref-type="fig"} The assessable surgical and medical patients were 1110 (53.9%) and 948 (46.1%), respectively. Of the total 2058 evaluable patients, 1104 (53.6%) were identified to be at-risk of VTE based on the ACCP risk criteria, including 680 (61.3%) surgical patients and 424 (44.7%) medical patients. A total of 1104 patients at risk of VTE were recruited, of which 68.9 per cent were males with median age 51 yr, median body mass index (BMI) 24.7 kg/m^2^, and median length of hospital stay 6 days ([Table I](#T1){ref-type="table"}). In patients from surgical wards, the major surgeries done during hospitalization were orthopaedic surgeries (19.1%) including hip/knee replacement, hip fracture, curative arthroscopy, and surgeries for other orthopaedic trauma. The major reasons for hospitalization were other medical conditions (22.4%) and cardiovascular disease including acute heart failure (17.8%). In patients from medical wards, the major reason for hospitalization was cardiovascular disease including acute heart failure (54.7%).

![ENDORSE study: Indian patient population. VTE, venous thromboembolism. ^\*^Based on hospital enrolment forms; † Based on patient enrolment logs, includes patients who did not meet protocol requirements (*e.g*. age, type of condition, or missing hospital chart); ‡ Includes patients in general surgical units, surgical ICUs, neurosurgery, gynaecology, and orthopaedics; and § Includes patients in other surgical wards](IJMR-136-60-g001){#F1}

###### 

Patients' characteristics and reasons for hospitalization

![](IJMR-136-60-g002)

[Table II](#T2){ref-type="table"} presents the risk factors for VTE prior to and during hospitalization. Before hospitalization, long-term immobility (3.3%), chronic pulmonary disease (3.2%) and obesity (3.0%) were the most common risk factors for surgical patients, while chronic pulmonary disease (18.8%) and chronic heart failure (10.5%) were the major risk factors for medical patients. The most common VTE risk factors reported in patients in surgical and medical wards during hospital stay were complete immobilization (46.5 vs. 36.1%), admission to intensive or critical care unit (29.4 vs. 62.3%), and immobilization with bathroom privileges (24.6 vs. 30.9%).

###### 

Risk factors for venous thromboembolism
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In patients from surgical wards, the most common contraindications to pharmacological prophylaxis were bleeding on hospital admission (7.2%) and intracranial bleeding (4.6%), while in patients from medical wards, clinically relevant renal impairment (9.2%) and hepatic impairment (3.3%), and low platelets count (3.3%) were the most common contraindications ([Table III](#T3){ref-type="table"}). According to the ACCP criteria for risk factors for bleeding, from the 1104 patients at risk for VTE, 79 patients (11.6%) from surgical wards and 42 patients (9.9%) from medical wards were considered to have contraindications to anticoagulant prophylaxis.

###### 

Contraindication to pharmacological prophylaxis
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Of the 1104 patients at-risk for VTE, only 192 (17.4%) received the ACCP-recommended prophylaxis. Of the 680 patients from surgical wards, only 126 (18.5%) received any VTE prophylaxis, and 111 (16.3%) received ACCP-recommended VTE prophylaxis. Of the 424 patients from medical wards, 95 (22.4%) received any VTE prophylaxis and 81 (19.1%) received ACCP-recommended VTE prophylaxis.

Overall prophylaxis in at-risk VTE patients was low. Anticoagulants were the commonly used type of prophylaxis ([Table IV](#T4){ref-type="table"}). Low molecular weight heparin (LMWH, 11.7%) was the most preferred choice of anticoagulant in surgical as well as medical wards patients, followed by unfractionated heparin (UFH, 5.3%). Among mechanical prophylaxis available, graduated compression stockings were used only in 35 (3.2%) patients.

###### 

Types of prophylaxis prescribed for the patients
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Discussion {#sec1-3}
==========

In the present study, we assessed the number of hospitalized patients with VTE risk in 10 selected hospitals in India. The study demonstrated high occurrence of patients at-risk for VTE in India. The proportion of Indian patients considered at risk for VTE (53.6%) was similar to that of the global patients at risk for VTE (51.8%)[@ref13]. We also assessed the current thromboprophylaxis practice in India in order to optimize practice patterns for appropriate use of thromboprophylaxis. The global ENDORSE data showed that 50.2 per cent at-risk patients received ACCP-recommended prophylaxis[@ref13], while in India, very low proportion of at-risk patients (17.4%) received ACCP-recommended prophylaxis. We observed that among at-risk patients, 18.5 per cent surgical and 22.4 per cent medical patients received any VTE prophylaxis. Similarly 16.3 per cent surgical and 19.1 per cent medical patients received ACCP-recommended thromboprophylaxis.

The Indian data from ENDORSE study revealed that despite a similar proportion of patients at risk in India and other participating countries, there is major underutilization of prophylaxis (17.4%) in India as compared to higher usage of prophylaxis globally (50.2%)[@ref13]. According to the ENDORSE global study, higher percentage of at-risk medical patients received ACCP-recommended prophylaxis countries such as Germany (70%), Colombia (64%), Spain (64%) and Switzerland (61%)[@ref14]--[@ref17]. Also, in case of at-risk surgical patients, Germany (92%), Hungary (87%), Spain (82%) and Switzerland (81%) showed high usage of ACCP-recommended prophylaxis[@ref14][@ref16]--[@ref18]. ENDORSE global data in hospitalized medically ill patients demonstrated that the prophylaxis use varied between the participating countries, and was associated with disease severity rather than medical diagnosis[@ref19]. Among the hospitalized surgical patients in ENDORSE global study, the rates of prophylaxis use varied according to surgery type and presence of comor-bidities[@ref20]. The Indian data are in agreement with the results of earlier studies from India and emphasize the underutilization of prophylaxis[@ref7]. The Prospective Registry on Venous thromboembolic Events (PROVE) study showed that only 7 per cent of patients with confirmed symptomatic DVT received appropriate thromboprophylaxis[@ref7]. Although critically ill patients require more intensive and prolonged thromboprophylaxis, earlier studies have demonstrated that only half the patients in multidisciplinary critical care units (44-47%) had received thrombo-prophylaxis[@ref21][@ref22].

The most common reasons for the underutilization might be bleeding complications as contraindications to anticoagulants[@ref23]. However, the inadequacy of thromboprophylaxis cannot be explained only by contraindications to anticoagulant use, since mechanical thromboprophylaxis was also underutilized. Earlier evidence has shown that LMWH is as effective and safe as UFH for treatment of VTE[@ref24][@ref25]. However, since LMWH is associated with lower incidence of thrombocytopenia and osteoporosis during long-term use, it is generally preferred over UFH despite its high cost[@ref26]. In the present study also, LMWH (11.7%) was used more frequently than UFH (5.3%).

The ENDORSE study had some potential limitations which should be considered while interpreting the results. Due to the cross-sectional design of the study, we could capture the data only during the hospital stay. Since there were no follow up visits, we could not evaluate the prophylaxis duration compliance with the recommendations of the ACCP guidelines. The data were collected from the patient charts and there was a possibility to include inaccurate data. Another limitation of the study was that some excluded younger patients also might have been at-risk for VTE. there was also a possibility of excluding at-risk patients who did not meet the ACCP criteria for VTE risk and recommendations for prophylaxis. Additionally, though we have collected reports of patients with standard bleeding risks, some physicians might have applied broader interpretation for not prescribing the anticoagulants.

In conclusion, our results showed a high occurrence of VTE risk in hospitalized Indian patients and underutilization of effective prophylaxis to a large extent. This confirms the need for increasing awareness about VTE risk, optimum risk assessment, and improved implementation of appropriate thromboprophylaxis in at-risk hospitalized patients. This will help in successful management of VTE and prevent the morbidity and mortality due to VTE.
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